REDWOOD CITY, Calif.--(BUSINESS WIRE)--Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device ...
A study of Proteus Digital Health’s ingestible pill sensor found it performed better than directly monitoring drug adherence among patients with tuberculosis taking monthslong maintenance therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback